Meningococcal disease: how to prevent and how to manage

被引：11

作者：

Balmer, P ^{[1
]}

Miller, E ^{[1
]}

机构：

[1] Ctr Communicable Dis Surveillance, Publ Hlth Lab Serv, Div Immunizat, London NW9 5EQ, England

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 2002年 / 15卷 / 03期

关键词：

D O I：

10.1097/00001432-200206000-00010

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Meningococcal disease is a significant problem in the paediatric population. The diagnosis of meningococcal disease can be problematic and progression of the disease can rapidly lead to a life-threatening illness. Despite the success of antibiotic treatment, mortality rates remain high. The development of protein-polysaccharide conjugate vaccines has significantly improved the success of vaccination in reducing the incidence of meningococcal disease. However, a comprehensive vaccine conferring protection against disease-associated serogroups remains elusive. The aim of this review is to highlight recent significant improvements in the prevention and management of meningococcal disease.

引用

页码：275 / 281

页数：7

共 93 条

[1] PREDICTORS OF OUTCOME IN ACUTE MENINGOCOCCAL INFECTION IN CHILDREN [J].

ALGREN, JT ;

LAL, S ;

CUTLIFF, SA ;

RICHMAN, BJ .

CRITICAL CARE MEDICINE, 1993, 21 (03) :447-452

[2]

BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926

[3]

Bolt P, 2001, ARCH DIS CHILD, V84, P90

[4] Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery [J].

Booy, R ;

Habibi, P ;

Nadel, S ;

de Munter, C ;

Britto, J ;

Morrison, A ;

Levin, M .

ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 85 (05) :386-390

[5] Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls [J].

Borrow, R ;

Southern, J ;

Andrews, N ;

Peake, N ;

Rahim, R ;

Acuna, M ;

Martin, S ;

Miller, E ;

Kaczmarski, E .

VACCINE, 2001, 19 (23-24) :3043-3050

[6] Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children [J].

Borrow, R ;

Goldblatt, D ;

Andrews, N ;

Richmond, P ;

Southern, J ;

Miller, E .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (03) :377-380

[7] Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection [J].

Borrow, R ;

Andrews, N ;

Goldblatt, D ;

Miller, E .

INFECTION AND IMMUNITY, 2001, 69 (03) :1568-1573

[8]

BORROW R, 2001, P 41 INT C ANT AG CH

[9] Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age [J].

Bramley, JC ;

Hall, T ;

Finn, A ;

Buttery, RB ;

Elliman, D ;

Lockhart, S ;

Borrow, R ;

Jones, IG .

VACCINE, 2001, 19 (20-22) :2924-2931

[10] The management of fever and petechiae: making sense of rash decisions [J].

Brogan, PA ;

Raffles, A .

ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (06) :506-507

← 1 2 3 4 5 6 7 8 9 10 →